BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Bitopertin readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Bitopertin\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05883748-9334@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Bitopertin: Phase 2/3 readout est. (NCT05883748)
DESCRIPTION:Bitopertin\, phase 2/3\, Erythropoietic Protoporphyria.\nStudy:
  HELIOS: Open-Label\, Long-Term Extension Study to Investigate the Safety\
 , Tolerability\, and Efficacy of DISC-1459 (Bitopertin) in Participants Wi
 th EPP or XLP\nEstimated primary completion: June 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/bitopertin#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT05883748
URL:https://assetmemo.bio/drug/bitopertin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
